Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy - Report - MDSpire
Advertisement
Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy
Clinical Report: Two-Year Assessment of Bimekizumab's Efficacy in Psoriasis
Overview
Bimekizumab demonstrated effectiveness in chronic plaque psoriasis, with 80.0% and 76.5% of patients achieving complete skin clearance at weeks 52 and 104, respectively. Drug survival rates were higher in biologic-naïve patients compared to those with prior biologic exposure.
Background
Chronic plaque psoriasis affects approximately 2-3% of the global population. Bimekizumab, a dual-targeted biologic agent, has shown promise in achieving complete skin clearance.
Data Highlights
Time Point
PASI100 Achievement
Week 52
80.0%
Week 104
76.5%
Key Findings
80.0% of patients achieved complete skin clearance (PASI100) at week 52.
76.5% of patients maintained PASI100 at week 104.
91.5% drug survival rate in biologic-naïve patients over 2 years.
Prior biologic exposure decreased long-term treatment retention to 64.0%.
Palmo-plantar involvement and nail psoriasis negatively impacted early complete skin clearance.
Concomitant proton pump inhibitor use was identified as an independent negative predictor for achieving early clearance.
Clinical Implications
Clinicians should consider prior biologic exposure and specific comorbidities when assessing treatment plans for psoriasis patients.
Conclusion
Bimekizumab shows efficacy in chronic plaque psoriasis over two years.
